Request Trial
15 April 2015Americas

PTAB instigates interference on Biogen multiple sclerosis treatment

The US Patent Trial and Appeal Board (PTAB) has instigated an interference proceeding between Biogen and Forward Pharma to determine who first invented a treatment for multiple sclerosis (MS).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB year in review: A shifting landscape and outlook for 2026
2 January 2026   With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.
Americas
5 ways the USPTO director is changing US innovation
24 December 2025   John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.
Americas
Mirum targets generics in quartet of suits over liver treatment
22 December 2025   Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
25 November 2025
Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025

More features

PTAB year in review: A shifting landscape and outlook for 2026
UPC: A review of 2025 and what to expect in 2026
Mental health in IP: ‘We have a clear picture of the problem’
From Edwards to Insulet: Three key medical device cases of 2025
Edwards v Meril: Behind the UPC’s landmark medtech showdown
5 ways the USPTO director is changing US innovation
EU unveils sweeping pharma, biotech, and medical device reforms
Mirum targets generics in quartet of suits over liver treatment